There are still many unanswered questions on the use of EGFR treatment in NSCLC E pidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is frequently overexpressed in nonsmall cell lung cancer (NSCLC). These receptors play an important role in tumour cell survival and activated phosphorylated EGFR results in the phosphorylation of downstream proteins that cause cell proliferation, invasion, metastasis, and inhibition of apoptosis. Expression appears to be dependent on histological subtypes, most frequently expressed in squamous cell carcinoma but also frequently expressed in adenocarcinomas and large cell carcinomas. 1 Not surprisingly, there are many published reports attempting to correlate the relationship between EGFR protein overexpression and survival. However, the data regarding the prognostic role of EGFR expression are inconsistent and confusing, with some reports indicating that EGFR is associated with poor survival while no prognostic association was seen in other reports.
In this issue of Thorax Nakamura et al carried out a meta-analysis of 18 studies (including nearly 3000 patients), reviewing whether EGFR overexpression has an impact on survival. Most of these reported studies evaluated EGFR protein expression by immunohistochemistry (IHC) and it is possible that different conclusions may reflect differences in incubation and detection methods, reagents, assay cut off points, and population studied with different stages. Nevertheless, EGFR overexpression was seen in 39% in adenocarcinoma, 58% in squamous cell carcinoma, and 38% in large cell carcinoma, and they concluded that EGFR protein overexpression using the IHC method was not associated with a poorer prognosis. However, we have less information about whether expression based on EGFR gene copy number or EGFR gene mutations impacts on survival. A recent report 3 suggests that EGFR mutations are not associated with poorer survival. However, investigators at the University of Colorado showed that the EGFR gene copy number quantified by fluorescence in situ hybridisation (FISH) may be correlated with a poorer prognosis. 1 A much more important issue for patients with NSCLC is whether a relationship exists between EGFR expression and survival benefit with EGFR inhibitor therapy. This might disadvantage patients with negative or low EGFR expression who might benefit from EGFR inhibitor treatment as most trials involving EGFR blockade preclude patients with no EGFR protein expression. Two EGFR inhibitors, gefitinib (Iressa) and erlotinib (Tarceva), have been approved in the United States for use as second line or third line treatment in advanced NSCLC. In the landmark BR21 randomised, placebo controlled, phase III study from NCI Canada, treatment with erlotinib improved median overall survival from 4.7 months to 6.7 months and 1 year survival rates from 22% to 31% in patients with advanced NSCLC who had progressive metastatic disease after receiving chemotherapy, but the status of EGFR protein expression was not predictive for survival benefit to erlotinib. 4 In retrospective studies related to gefitinib from the IDEAL trials, no association was observed between EGFR protein expression, response, and survival benefit. 5 6 In both the BR21 and IDEAL trials, higher response rates were seen in patients who were never smokers, female, Asians, and with adenocarcinomatous histology. This is in contrast to a study from Colorado which showed a significant correlation between levels of EGFR expression (using a different antibody) and sensitivity to gefitinib. 7 The group also showed that quantifying EGFR gene copy number with FISH technology offers a better prediction of sensitivity and survival to EGFR inhibitors, but this needs to be proved in prospective large scale randomised studies. The US Food and Drug Administration (FDA) recently revised the approval of gefitinib labelling to be used only in patients who had already taken the medicine because, in a large recently reported randomised trial (ISEL, Iressa Survival Evaluation in Lung Cancer) involving nearly 1700 patients, gefitinib did not improve survival in the general study population. However, subgroup analyses showed that gefitinib significantly improved survival in patients of Asian ethnicity and in those who had never smoked. 12 In the past 12 months three groups have reported an important association between somatic mutations in the EGFR gene at the tyrosine kinase domain and a dramatic response to gefitinib and erlotinib. [8] [9] [10] The EGFR domain mutations frequently involved either inframe deletions in exon 19, single missense mutations in exon 21, or inframe duplications/insertions in exon 20 and were not associated with clinical stage or survival. 3 Interestingly, these mutations were statistically more frequent in never smokers than in smokers (51% v 14%), in adenocarcinomas than in other histological types (40% v 3%), in patients of East Asian ethnicity (30% v 8%), and in women than in men (42% v 14%). 3 These findings are very similar to the clinical characteristics of patients responding to gefitinib or erlotinib treatment in the IDEAL and BR21 studies, respectively. [4] [5] [6] Despite the dramatic responses to such inhibitors, most patients ultimately relapse. Similar to the paradigm with imatinib treatment in gastrointestinal stromal tumours and chronic myeloid leukaemia, this was recently shown to be due to acquisition of a second mutation (at position T790M) in the catalytic cleft of the EGFR tyrosine kinase domain, thereby preventing access by gefitinib. 11 There are still many important unanswered questions concerning EGFR treatment. While the association between these mutations and the dramatic response to gefitinib or erlotinib has been shown, we are still unclear why survival benefit is seen in the majority of the BR21 patients with stable disease with symptomatic response who appear to have no EGFR mutations when treated with erlotinib. Indeed, in the BR21 study, survival after treatment with erlotinib was not influenced by EGFR gene mutations. 4 Moreover, in a study reported by the Colorado group, 40% of their patients with EGFR mutations developed progressive disease and 32% of their nonmutated EGFR group had disease control following gefitinib treatment. 7 We still do not know whether all the described mutations are of equal clinical relevance. Based on the current clinical data available, we must therefore acknowledge that EGFR mutations or expression status per se do not quantify use as predictive markers for selection of NSCLC patients to treatment with EGFR inhibitors. A meta-analysis of the data obtained from the BR12 and ISEL studies may indicate whether EGFR expression confers a survival advantage in patients treated with EGFR inhibitors. The findings described above refer to relapsed NSCLC patients. However, we do not have any data on the role of EGFR monotherapy when used as first line treatment, particularly in poor performance patients or as maintenance treatment following chemotherapy. Prospective large scale clinical studies with translational component need to be performed to identify the most optimal paradigm for selection of patients for treatment with EGFR inhibitors. Defining the mechanisms of resistance to EGFR inhibitors, coupled with identifying the molecular and clinical profile of responding versus non-responding patients in ongoing trials, remains a very important priority. A randomised phase III study examining the role of EGFR inhibition as first line treatment for patients with advanced NSCLC is currently in progress in the UK, attempting to answer some of these questions. The seminar is free for COPE members and £30.00 + VAT for non-members. Numbers are limited and early booking is advisable. For registrations or more information please contact the COPE Secretary at cope@bmjgroup.com or call 020-7383-6602 For more information on COPE see www.publicationethics.org.uk
